Assessment of quality of life in advanced gastro-intenstinal cancer patients receiving chemotherapy

[Speaker] Ritu Bala:1
[Co-author] Harminder Singh:1, Kuhu Verma:1
1:Pharmacology, no, India

Background: The objective of this study is to assess the common gastro-intenstinal (GI) symptoms & quality of life (QOL) in advanced GI tract cancer patients with the help of MD Anderson Symptom Inventory (MDASI-GI) validated scale. Methodology: This is a cross sectional, non-interventional and observational study. A total of 48 patients were interviewed about the GI symptoms and their effect on day to day life with MDASI-GI scale after taking written informed consent from patients. Result: The study population consisted of 23 males and 25 females with an average age of 48.16 years. Among cancer category, 52.08% were of Upper GI tract cancer. Symptom-wise 59.12% showed mild category of GI symptoms. According to QOL, 65.12% of the patients mildly affected with reference to day to day activities. . Out of a total of 48 patients, 25 had esophageal/upper GI cancer; 10 were of hepatobiliary followed by 8 having colorectal cancer; and 5 with buccal mucosal cancer. 25 patients were treated with Cisplatin/Oxaliplatin with 5-Fluorouracil chemotherapy; 11 patients received Gemcitabine; 8 were given Paclitaxel; and 4 received Methotrexate. Conclusion: The result of this study shows that most of GI symptoms due to GI cancer were in mild to moderate category and can be managed with prior knowledge of their occurrence. Managing GI symptoms will not ameliorate the disease process but certainly will improve the daily activities and add to improved quality of life.

Advanced Search